Search Elevated Serum Alkaline Phosphatase as a Marker of Prenatal Intervillositis Chronic Histiocytic (IHC)

U

University Hospital, Lille

Status

Completed

Conditions

Chronic Histiocytosis

Study type

Observational

Funder types

Other

Identifiers

NCT02668120
2014-A01550-47 (Other Identifier)
2013_18

Details and patient eligibility

About

Background : Chronic histiocytic intervillositis is a rare placental disease linked with poor perinatal outcome. In a recent study, a major antenatal increased alkaline phosphatase was suspected in patients affected by chronic histiocytic intervillositis. This increase may correspond to the release of alkaline phosphatase by the syncytiotrophoblaste prejudiced in this pathology. Aim : To confirm the association between high levels of alkaline phosphatase and the occurrence of chronic histiocytic intervillositis.

Full description

Single-center study of case-control comparing three groups of patients matched for gestational age at the time of sampling. The case group will be composed of patients who experienced chronic histiocytic intervillositis which an alkaline phosphatase assay is available during pregnancy (retrospective recruitment). Two control groups will be prospectively: The first will include patients whose pregnancy is low risk. The second will consist of pathological pregnancies (IUGR, Preeclampsia and Death In Utero). All patients will have a blood sample with determination of serum alkaline phosphatase activity and examination of the placenta at delivery.

Enrollment

54 patients

Sex

Female

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Patient aged 18 years or more
  • Having signed a free and informed consent
  • Enjoying a social security scheme

Inclusion criteria for cases:

  • Patient who gave birth at the Lille University Hospital between 2000 and 2009.
  • Lesion of intervillositis chronic histiocytic (IHC) diagnosed during histological examination of the placenta.
  • An alkaline phosphatase assay during pregnancy is available and has been achieved at University Hospital of Lille.
  • Prior information and not opposition of the patient to the secondary use of data collected in medical file.

Inclusion criteria for low-risk pregnancy :

  • No pathological obstetric history, no current pregnancy complications
  • Followed antenatal clinics at the Lille University Hospital
  • A gestational age corresponding to one of the cases (pairing ± 1 week)
  • No chronic intervillositis after pathological examination of the placenta

Inclusion criteria for high-risk pregnancy:

  • Patient hospitalized in the maternal-fetal pathology of the Lille University Hospital Service
  • Presence of IUGR, Death in Utero or severe preeclampsia with fetal repercussion
  • A gestational age corresponding to one of the cases (pairing ± 1 week)
  • No chronic intervillositis after pathological examination of the placenta

Exclusion criteria

  • Twin pregnancy
  • Liver disease in the interrogation
  • Lack of consent of the patient
  • Patient not covered by a social security scheme
  • Patient minor
  • Patient under guardianship

Trial design

54 participants in 3 patient groups

Cases
Description:
Patients with chronic histiocytic intervillositis during pregnancy followed at University Hospital of Lille. Alkaline phosphatase assay was performed during pregnancy and is documented in the medical record. The cases are included retrospectively.
Low-risk pregnancy
Description:
Patients with a low risk pregnancy followed at University Hospital of Lille and recruited prospectively in prenatal consultation. These patients have no pathological obstetric history.
High-risk pregnancy
Description:
Patients with severe pregnancy complication (IUGR, Preeclampsia or Death in Utero), but without chronic intervillositis, and hospitalized in the maternal-fetal pathology department of the University Hospital of Lille. They are recruited prospectively.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems